RLAY Stock Forecast & Price Target

Relay Therapeutics is viewed favorably because its Dynamo platform targets historically intractable proteins and is producing clinically meaningful data across precision oncology and genetic disease, especially with zovegalisib in vascular anomalies and breast cancer. The company’s valuation appears disconnected from fundamentals given short interest of 24.51% of the public float, while the zovegalisib program has already shown strong efficacy and could support accelerated approval if the anticipated end-2026 update confirms prior results. Financially, 2Q26 net loss was $0.41 per share, R&D and SG&A were $76.5M and $14.7M, and $910.9M in cash provides runway into 2029, reducing execution risk ahead of multiple catalysts.

Relay Therapeutics is constrained by a highly speculative valuation framework that depends on a 75% probability of success for zovegalisib in 1L and 2L PI3Kα+, HR+, HER2- mBC, despite the inherent failure risk of clinical-stage drug development. The cited DCF outputs of $6.3B and $6.2B projected market value rest on a 10% discount rate, 1.0% terminal growth rate, and 29% effective tax rate, but those inputs cannot offset risks of negative clinical data, delayed development, and setbacks in later-stage or earlier-stage candidates. The outlook is further weakened by FDA and foreign approval uncertainty, intense competition from better-resourced biotechnology and pharmaceutical peers, and the likelihood of additional equity financing that could dilute existing shareholders.